Acquisition Pending
Gyre Therapeutics acquisition of Cullgen
US$300m equity value
Announced 2 Mar 2026
Advisers
- Target
- Cullgen
- Acquirer
- Gyre Therapeutics
- Target based in
- United States (unverified)
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Drug Development
In the league tables
Similar deals
- Dimerix acquisition of MTX652 Jul 2026 · US$292m · Biotech
- Bayer acquisition of Perfuse Therapeutics May 2026 · US$300m · Biotech
- Eli Lilly and Company acquisition of CrossBridge Bio Apr 2026 · US$300m · Biotech
- BioMarin Pharmaceutical acquisition of Alesta Therapeutics Aug 2026 · US$275m · Biotech
- Amneal Pharmaceuticals acquisition of Kashiv BioSciences Apr 2026 · US$375m · Biotech

